Sotalol hydrochloride injection 15 mg/mL for intravenous administration (IV sotalol) from AltaThera Pharmaceuticals is a parenteral formulation of the commonly prescribed oral sotalol (Betapace or Betapace AF). It is indicated for life-threatening arrhythmias and maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation/atrial flutter. The label contains dosing recommendations for children with supraventricular and/or ventricular tachycardias. In March 2020, IV sotalol received FDA approval for new patient initiation or dose escalation to rapidly achieve CMax steady-state and reduce the hospital stay from 3 days to 1 day.

AltaThera Pharmaceuticals LLC